From TV Studio to Brain Science Hub
Billionaire investor Bill Ackman and his wife, architect Neri Oxman, are creating a medical center on Manhattan's Upper West Side dedicated to the comprehensive study of the human brain. Through his Pershing Square Foundation, Ackman has spent $188 million on a former Chrysler showroom at 125 West End Avenue and is in contract to buy the neighboring building—once the ABC studio that hosted live tapings of The View—for an additional $70 million. Together the properties offer roughly 700,000 square feet for labs, surgical suites, and conference rooms, dwarfing Columbia University's nearby 450,000-square-foot Zuckerman Institute.
The project is deeply personal. Oxman lost her mother to Alzheimer’s, and in February, Ackman’s eldest daughter, Lucy, suffered a catastrophic brain hemorrhage that crushed her optic nerve and left her unable to speak. Ackman has said he hopes the institute will one day learn from her medical records. But the timing also reflects a dramatic cooling in the market for specialized lab space: with about a quarter of New York’s medical-lab buildings sitting vacant, according to CBRE, Ackman appears to have secured the sites at a steep discount—brokers estimate he paid less than half of what the developers spent on renovations.
Ackman’s vision goes beyond philanthropy. He is structuring the center as a new kind of research institution—one that spins out for-profit companies developing devices, molecules, and treatments for brain injury and stroke. Researchers would share in the profits from their discoveries, much like startup founders. Mount Sinai Health System, whose own Mount Sinai West hospital is nearby, will partner with the center, though the exact contours of the relationship remain unclear. The institute’s board will include biohacker Andrew Huberman, a controversial figure whose history with women has drawn scrutiny.
Why Ackman's Institute Could Reshape Medical Research—and Real Estate
Ackman’s Upper West Side Campaign
Manhattan’s medical corridor clusters on the far East Side, where doctors can move quickly between hospitals. Ackman and Oxman live in a Norman Foster–designed penthouse on West 77th Street; Ackman’s office is on West 55th Street. The new institute sits almost exactly between them, raising the possibility that convenience—and a desire to reshape the neighborhood’s institutional landscape—drove the site choice. By planting a major brain center on the West Side, Ackman is replicating the kind of city-shaping moves made by Gilded Age barons who relocated entire industries to suit their own interests.
The Real-Estate Discount Behind the Deal
The two buildings were purchased by developers Taconic Partners and Nuveen Real Estate for $230 million in 2019. They overhauled the space at great expense but managed to lease only half of one of seven floors. With lab vacancy rates at roughly 25% citywide—and one Long Island City development that cost an estimated $200 million recently selling for just $87 million—the sellers likely took a significant loss. Bill Hartman, a CBRE vice-chairman, estimates Ackman acquired the properties for less than half of the developers’ total investment. For Ackman, who previously tried to flip his own office building for double what he paid, this looks like a classic value play.
A For-Profit Spinoff Model
Traditional academic medical centers typically own the intellectual property their researchers generate. Ackman’s center would let scientists share in the equity of any spinoff companies, mirroring the incentives that drive biotech startups. If successful, the model could attract entrepreneurial researchers who currently gravitate toward the private sector and accelerate the translation of lab discoveries into treatments. It also partially insulates the institute from the federal funding cuts that Ackman’s political allies have championed.
Mount Sinai’s Unclear Role and Reputational Baggage
Mount Sinai has not issued a press release about the partnership, suggesting negotiations are still fluid. The health system’s brand could lend credibility, but it also exposes Mount Sinai to the reputational risks that follow Ackman. The investor helped fund Robert F. Kennedy Jr.’s presidential campaign, endorsed his vaccine skepticism, and spent this week retweeting headlines from the controversial trial of Dr. Anthony Fauci. Board member Andrew Huberman has faced allegations of problematic behavior with women. An independent center allows Ackman to hire scientists who might be blackballed elsewhere—such as the disgraced former MIT professor he already backs—without institutional pushback. For a medical institution, that independence cuts both ways.
What the Brain Center Means for Developers, Doctors, and Policy
- For real-estate developers: The lab market collapse—CBRE reports 25% vacancy—makes this an opportune moment to convert underperforming office space into life-sciences hubs, but anchor tenants like Ackman’s foundation can bring significant branding risks.
- For Mount Sinai: The hospital system must clarify its operational and financial commitment soon. Any public association with Ackman’s political endorsements or his board picks could alarm donors and patients; a detailed governance agreement is essential.
- For policymakers: As federal research funding is dialed back, private, profit-seeking institutes such as this one may fill the gap. Regulators should watch whether the spin-off model compromises patient safety or ethical standards in the pursuit of commercial returns.
- For the medical research community: The promise of equity could pull top neuroscientists away from traditional universities. Institutions that rely on federal grants may need to reconsider how they reward inventors to retain talent.
- For investors in brain health: Ackman’s center represents a new class of heavily capitalized, founder-driven research platforms. Its ability to blend real-estate arbitrage with drug-discovery upside merits monitoring, especially if early spin-offs attract venture funding.
Risk & Opportunity Assessment
| Commercial Risk | Medium | While the property was acquired at a discount, the center's ongoing operational funding is not guaranteed. If the partnership with Mount Sinai fails to materialize fully, the lab space could remain underutilized, eroding the initial real-estate advantage. |
| Competitive Risk | Medium | New York's existing neuroscience powerhouses, such as Columbia's Zuckerman Institute and the NYU Langone network, already compete for top researchers and grant money. Ackman's equity-sharing model may attract talent, but established institutions have deeper academic reputations. |
| Regulatory Risk | Medium | Spin-off companies developing drugs and devices will face FDA review. Moreover, if federal policy continues to restrict research funding, the broader life-sciences ecosystem could shrink, limiting the center's collaborative opportunities. |
| Reputation Risk | High | Ackman's public backing of RFK Jr.'s anti-vaccine campaign, his promotion of contentious figures like Andrew Huberman, and his recent attacks on Fauci could stigmatize the institute among mainstream researchers, patients, and potential donors, complicating recruitment and partnerships. |
| Technology Disruption | Low | The center itself is not a technology platform but a bricks-and-mortar research facility. Its potential to disrupt health care lies in the therapies it may produce, an outcome that remains years away and highly uncertain. |
| Commercial Opportunity | High | Ackman effectively paid less than half of the properties' development cost, providing immediate embedded value. The profit-sharing structure could produce lucrative returns if even a single spin-off succeeds, and the lab-oversupply market now favors well-capitalized buyers. |
Comments 0